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Long-term peritoneal dialysis (PD) leads to histological changes in the peritoneal membrane.  
Angiogenesis and inflammation caused by glucose degradation products (GDPs) play crucial 
roles in peritoneal fibrosis.  One such GDP is methylglyoxal (MGO), which enhances the 
formation of advanced glycation end products (AGEs).  AGEs bind to their receptor (RAGE) 
and activate nuclear factor-B (NF-B), which is a key regulator of angiogenesis and 
inflammation.  Recent studies have indicated that (-)-epigallocatechin gallate (EGCG), a tea 
polyphenol, inhibits angiogenesis and inflammation.  Here, we examined whether EGCG 
suppresses peritoneal fibrosis in mice. 
Based on preliminary examination, 2 mL of 40 mM MGO or PD fluid was injected 
intraperitoneally and EGCG (50 mg/kg) or saline was injected subcutaneously for 3 weeks.  
In comparison to PD fluid + saline-treated mice, the peritoneal tissues of MGO + saline-
treated mice showed marked thickening of the submesothelial compact zone.  In the 
submesothelial compact zone of the MGO + saline-treated mice, CD31-positive vessels and 
vascular endothelial growth factor-positive cells were significantly increased, as were 
inflammation, F4/80-positive macrophages, and monocyte chemotactic protein-1.  Moreover, 
8-hydroxydeoxyguanosine, a marker of reactive oxygen species, and NF-B, determined by 
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Southwestern histochemistry, in the submesothelial compact zone were also increased in 
MGO + saline-treated mice.  These changes were attenuated in MGO + EGCG-treated mice. 
We demonstrated that EGCG treatment suppresses peritoneal fibrosis via inhibition of NF-
B.  Furthermore, EGCG inhibits reactive oxygen species production.  The results of this 
study indicate that EGCG is a potentially novel candidate for the treatment of peritoneal 
fibrosis. 
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Peritoneal dialysis (PD) is a beneficial therapy for end-stage renal disease.  However, long-
term PD therapy leads to histopathological changes in the peritoneum, such as peritoneal 
fibrosis and vasculopathy [1, 2].  Although the mechanisms underlying these structural 
changes have not been fully elucidated, the angiogenesis and inflammation caused by the 
glucose degradation products (GDPs) in PD fluid play crucial roles [3, 4].  Some GDPs, such 
as methylglyoxal (MGO), promote generation of advanced glycation end products (AGEs) 
[5-7].  Recent studies have revealed that peritoneal deposition of AGEs increases with the 
duration of PD, and may correlate with the development of peritoneal fibrosis [4, 6, 8]. 
Growing evidence indicates that AGEs evoke angiogenesis through stimulating vascular 
endothelial growth factor (VEGF), and also induce proinflammatory cytokines [4, 9].  The 
interaction of AGEs with the receptor for AGEs (RAGE) results in peritoneal damage in 
diabetic and uremic rats [10-12], and causes upregulation of the transcription factor, nuclear 
factor-B (NF-B) [9, 12, 13].  NF-κB plays a key role in regulating target genes, such as 
VEGF, monocyte chemotactic protein-1 (MCP-1), interleukin (IL)-1, and IL-6 [9]. 
One of the most common GDPs found in PD fluid is MGO, which enhances the formation 
of AGEs [7].  Previous investigations of rat MGO-induced peritoneal fibrosis have revealed 
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thickening of the peritoneum and ultrafiltration failure; these are major symptoms of 
peritoneal fibrosis in PD patients [7, 14].  Although several other peritoneal fibrosis models 
exist, we established a mouse MGO-induced peritoneal fibrosis model in the present study.  
The mouse offers critical advantages as an experimental model for mammalian biology, 
including low cost, fast turnover, easy breeding, and multiple possibilities of genetic 
manipulation. 
Although the mechanism underlying MGO-induced peritoneal fibrosis has not been fully 
elucidated, previous research has indicated that tissue damage with inflammation, 
subsequently followed by tissue repair with excessive proliferation of myofibroblasts [14], 
and angiogenesis play important roles [2, 4, 15].  The accumulation of AGEs in the MGO-
induced rat peritoneal fibrosis model has been demonstrated [7], and oxidative stress has been 
shown to play a key role in the production of AGEs, and also in the cell signaling of 
downstream RAGE [16].  Furthermore, increased NF-B expression has been observed in 
infiltrating cells of the submesothelial compact zone, and the degree of submesothelial NF-
B expression was found to correlate significantly with the progression of peritoneal fibrosis 
in PD patients [13]. 
Among tea polyphenols, epigallocatechin-3-gallate (EGCG) is known to have favorable 
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effects, including the prevention of angiogenesis, inflammation, and oxidation, at least in part, 
through the suppression of NF-B activity [17-19].  Studies using a CCl4-induced liver injury 
model [20], a bleomycin-induced pulmonary fibrosis model [21], and a cardiac hypertrophy 
model [22] have demonstrated that EGCG ameliorates fibrosis effectively.  Moreover, EGCG 
significantly decreased AGE-stimulated gene expression [19].  In the present study, we 
examined the effect of EGCG on peritoneal fibrosis in a mouse MGO-induced model.  In 
addition, we investigated the effects of EGCG on angiogenesis, inflammation, and oxidative 
stress, to elucidate the inhibitory mechanisms of EGCG for peritoneal fibrosis.
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2. Materials and methods 
2.1. Animals 
The animals used in this study were male C57/BL6 mice (10 weeks of age, weighing 
approximately 25 g; Japan SLC Inc., Shizuoka, Japan).  The animals had free access to 
laboratory chow and tap water, and were housed in a light- and temperature-controlled room 
in the Biomedical Research Center, Center for Frontier Life Sciences, Nagasaki University 
School.  The experimental protocol was inspected by the Animal Care and Use Committee of 
Nagasaki University School, and approved by the President of Nagasaki University School 
(Approval number: 1003301048). 
 
2.2. Reagents 
PD fluid containing 2.5% glucose was made by mixing Dianeal® N PD-2 1.5 (Baxter, Tokyo, 
Japan) and 50% glucose solution.  MGO (155558; MP Biomedicals LLC, Illkirch, France) 
was dissolved with PD fluid.  EGCG (70935; Cayman Chemicals, MI, USA) was dissolved in 
saline. 
Following purification with a 0.2-m pore-size filter, the PD fluids with or without MGO 
were prepared and adjusted with HCl daily to pH 5.0, immediately prior to injection. 
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3,3’-diaminobenzidine-4HCl (DAB) and ethylenediaminetetraacetic acid (EDTA) were 
purchased from Dojin Chemical (Kumamoto, Japan).  Tris-HCl, bovine serum albumin 
(BSA), yeast transfer RNA, salmon testis DNA, normal sheep immunoglobulin G (IgG), and 
Brij 35 were purchased from Sigma Chemical (St. Louis, MO, USA).  All other reagents were 
purchased from Wako Pure Chemicals (Osaka, Japan). 
 
2.3. Antibodies 
The following first antibodies were used for immunohistochemistry: (1) mouse anti- 
carboxy methyllysine (CML) (one of AGEs derived from MGO) antibody, diluted 1/50 
(KH011; Dojin Chemical); (2) rabbit anti-RAGE antibody, diluted 1/800 (AB5484; Millipore, 
CA, USA); (3) rabbit anti-type III collagen antibody, diluted 1/400 (LB-1393; LSL Co., 
Tokyo, Japan); (4) mouse anti--smooth muscle actin (-SMA) antibody, diluted 1/100 
(A2547; Sigma), used as a marker of myofibroblasts; (5) rabbit anti- transforming growth 
factor- (TGF- antibody, diluted 1/100 (sc-146; Santa Cruz, CA, USA); (6) mouse anti-8-
hydroxydeoxyguanosine (8-OHdG) antibody, diluted 1/100 (MOG-100P; Japan Institute for 
the Control of Aging, Tokyo, Japan), used as a marker of oxidative stress; (7) rat anti-mouse 
CD31/PECAM-1 antibody, diluted 1/50 (sc-1506; Santa Cruz), used as a marker of 
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endothelial cells; (8) rabbit anti-VEGF antibody, diluted 1/100 (sc-152; Santa Cruz); (9) rat 
anti-F4/80 antibody, diluted 1/50 (MCA497; Serotec, Oxford, UK), used as a marker of 
mouse macrophages; (10) goat anti-mouse MCP-1 antibody, diluted 1/100 (sc-1784; Santa 
Cruz); and (11) sheep anti- digoxigenin (DIG) horseradish peroxidase (HRP)-conjugated 
sheep antibody (11207733910; Roche, Mannheim, Germany). 
The following antibodies were used as second or third antibodies: (1) HRP-conjugated 
swine anti-rabbit IgG antibody (P0399; Dako, Glostrup, Denmark); (2) The peroxidase-
antiperoxidase reaction (PAP, Z0113; Dako); (3) HRP-conjugated rabbit anti-rat IgG antibody 
(Z0147; Dako); (4) HRP-conjugated goat anti-mouse IgG antibody (P0447; Dako). 
 
2.4. Administration of PD fluid and EGCG 
Mice were divided into 4 groups: (1) PD fluid + saline group (n = 6), defined as the control 
group; (2) PD fluid + EGCG group (n = 4); (3) PD fluid + MGO + saline group (n = 6), 
defined as the MGO group; and (4) PD fluid + MGO + EGCG group (n = 6), defined as the 
EGCG group.  Mice received PD fluid (100 mL/kg) with or without dissolved MGO (40 mM) 
intraperitoneally for 15 days, 5 consecutive days per week as described previously [7].  Mice 
also received saline or 50 mg/kg EGCG in saline subcutaneously for 21 days daily.  The dose 
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and interval for MGO injection were selected based on pilot studies. 
Mice were sacrificed at day 22.  The peritoneal tissues were dissected out and fixed in 4% 
paraformaldehyde in phosphate-buffered saline (PBS) (pH 7.4). 
 
2.5. Histological analysis and immunohistochemistry 
For histrological examination, 4-m-thick paraffin-embedded tissues were stained using the 
Masson-trichrome method. 
An indirect immunohistochemical technique was used for CML, type III collagen, -SMA, 
8-OHdG, and F4/80.  The indirect staining was performed as described previously [15, 23].  
In brief, deparaffinized tissue sections were incubated for 30 min with a blocking buffer 
containing 5% normal goat serum, 5% fetal calf serum, 5% BSA, and 20% normal swine 
serum in PBS.  The sections were then reacted with the primary antibodies, and diluted in the 
same blocking buffer.  Following reaction with anti-type III collagen antibody for 1 h at room 
temperature, sections were reacted with HRP-conjugated swine anti-rabbit immunoglobulin 
antibody diluted 1/50, for 30 min at room temperature.  The peroxidase-antiperoxidase 
reaction diluted 1/100 was used.  For F4/80, sections were reacted with HRP-conjugated 
rabbit anti-rat immunoglobulin antibody and HRP-conjugated swine anti-rabbit 
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immunoglobulin antibody, following reaction with anti-F4/80 antibody for 1 h at room 
temperature.  For CML, -SMA, and 8-OHdG, sections were reacted with primary 
antibodies overnight at room temperature, and HRP-conjugated goat anti-mouse 
immunoglobulin antibody diluted 1/50, for 1 h at room temperature. 
For RAGE, TGF- CD31, VEGF, and MCP-1, tissues were stained by an avidin-biotin 
complex technique using a Vectastain Elite ABC kit (Vector Laboratories, CA, USA), 
following reaction with the primary antibody as described previously [15, 23].  In brief, all 
primary antibodies except for MCP-1 were reacted for 1 h at room temperature.  For MCP-1, 
the primary antibody was reacted overnight at 4°C. 
Reaction products were visualized by treating sections with 100 L of 30% hydrogen 
peroxide and 50 mg of DAB.  Finally, the sections were counterstained with methyl green and 
mounted. 
 
2.6. Southwestern histochemistry for NF-B 
The following single-strand (ss)-oligo-DNAs were synthesized with the specific consensus 
sequence for the NF-B binding site (5′-GATCGAGGGGGACTTTCCCTAGC-3′ and 5′-
GCTAGGGAAAGTCCCCCTCGATC-3′) [24].  Double-strand (ds)-oligo-DNA was 3′-
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labeled with DIG.  The synthesized ss-oligo-DNAs were purchased from BEX (Tokyo, Japan).  
For annealing of complementary ss-oligo-DNAs to ds-oligo-DNA, the ss-oligo-DNAs were 
dissolved in 10 mmol/L of Tris-HCl buffer (pH 7.4), denatured for 10 min at 100°C, and 
gradually cooled to room temperature. 
Southwestern histochemistry was performed as described previously [25-27].  In brief, 
deparaffinized sections (4-m-thick) were treated in a microwave oven with citrate buffer 
(pH 6.0) at 95°C for 15 min.  The sections were then washed in PBS and immersed in a pre-
incubation buffer containing 5% nonfat milk dissolved in 10 mmol/L of Tris-HCl (pH 7.4) 
with 300 mmol/L of NaCl and 1 mmol/L of EDTA for 1 h.  Next, the sections were incubated 
overnight with the probe dissolved in the pre-incubation buffer at a concentration of 1 g/mL.  
The sections were then washed twice with pre-incubation buffer, and 4 times with 0.075% 
Brij in PBS.  Then the sections were incubated in a blocking buffer containing 5% BSA, 500 
g/mL of normal sheep IgG, 100 g/mL of yeast transfer RNA, and 100 g/mL of salmon 
sperm DNA in PBS for 1 h.  To visualize hybridized DNA-oligo probes, the sections were 
immunohistochemically stained with anti-DIG HRP-conjugated sheep antibody, diluted 1/100 
in blocking buffer, for 2 h.  After 4 washes with 0.075% Brij in PBS, we performed a color 
reaction with 100 mmol/L of phosphate buffer (pH 7.6), containing 50 mg of DAB and 33 L 
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of 30% hydrogen peroxide.  To enhance the reaction, we added 2 mL of 0.5% (v/v) nickel 
ammonium sulfate solution and 2.5 mL of 0.5% (v/v) cobalt chloride solution.  To evaluate 
the specificity of the probe for NF-B, we also used a mutated probe (5′-
GATCGAGGAAGACTTTCCCTAGC-3′ and 5′-GCTAGGGAAAGTCTTCCTCGATC-3′) 
[24].  Moreover, we hybridized some sections with the probe in the presence of an excess 
amount of non-labeled homologous ds-oligo-DNA, as described previously [26, 27]. 
 
2.7. Morphometric analysis 
To assess the thickening of the submesothelial compact zone, we used image analysis 
software (Lumina Vision Ver. 2.04; Mitani Corp., Fukui, Japan) following Masson-trichrome 
staining.  We measured the thickness of the submesothelial compact zone at 5 randomly 
selected positions in each tissue at ×200 magnification, and averaged the results. 
In each sample, we counted the numbers of RAGE-expressing cells, -SMA-expressing 
cells, TGF--expressing cells, 8-OHdG-expressing cells, CD31-positive vessels, VEGF-
expressing cells F4/80-positive macrophages and MCP-1-expressing cells in 5 fields at ×200 
magnification.  The results for each tissue were averaged.  For CML and type III collagen, we 
selected 5 areas in each tissue and performed semi-quantitative estimation of the intensity of 
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each protein with Lumina Vision. 
Finally, we selected 5 areas in each tissue and evaluated NF-B-activated cells with Lumina 
Vision. 
 
2.7. Statistical analysis 
Data are expressed as mean ± standard error of the mean (SEM).  Differences among groups 
were examined for statistical significance using repeated measures analysis of variance 
(ANOVA) (Bonferroni/Dunn test).  A p value <0.05 denotes a statistically significant 
difference.  All statistical analyses were performed with Stat View version 5.0 software (SAS 





 3.1. Morphological examination following Masson-trichrome staining 
In the normal and control mice, the peritoneal tissue consisted of a peritoneal mesothelial 
monolayer and sparse connective tissues below this layer (Fig. 1A and B).  Compared to the 
control group, the peritoneal tissue of the MGO group showed significant thickening of the 
submesothelial compact zone and the presence of numerous cells (Fig. 1C and F).  The 
thickness of the submesothelial compact zone in the EGCG group was significantly lower 
than that of the MGO group (Fig. 1D and F).  To assess the toxicity of EGCG, we analyzed 
the PD fluid + EGCG group.  Repeated injections of EGCG had no significant effect on the 
peritoneum (Fig. 1E and F). 
 
3.2. Accumulation of CML and expression of RAGE 
We observed very little CML deposition in the peritoneal tissues of the control group (Fig. 
2A and D).  The MGO group showed intense staining of CML in the peritoneum (Fig. 2B and 
D), whereas the EGCG group showed reduced intensity of CML staining (Fig. 2C and D). 
The number of RAGE-expressing cells was significantly higher in the MGO group than in 
the control group (Fig. 2E, F, and H), but significantly lower in the EGCG group than in the 
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MGO group (Fig. 2F, G, and H). 
 
3.3. Expression of type III collagen, -SMA, and TGF- 
In the control group, type III collagen expression in the submesothelial compact zone was 
equivalent to that of normal mice (Fig. 3A).  In the MGO group, type III collagen was 
diffusely expressed, and the positive areas were significantly larger than those of the control 
group (Fig. 3B and D).  EGCG administration significantly reduced the expression of type III 
collagen (Fig. 3C and D). 
Previous studies have shown that peritoneal myofibroblasts and mesothelial cells produce 
collagen, and that collagen deposition is mainly due to myofibroblasts [28, 29].  Thus, we 
investigated -SMA-expressing cells as a marker of myofibroblasts.  In the MGO group, we 
observed the expression of -SMA in vascular smooth muscle cells, and also numerous -
SMA-expressing myofibroblasts (Fig. 4A and Table).  On the contrary, the EGCG group 
contained markedly fewer -SMA-positive myofibroblasts (Fig. 4B and Table).  We also 
investigated fibroblast specific marker-1 (FSP-1) as an immunohistochemical marker of 
fibroblasts and myofibroblasts.  The number of FSP-1 positive cells was greater than that of 
-SMA positive cells in the submesothelial compact zone (data not shown).  This suggested 
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that not only myofibroblasts but also fibroblasts were present in the peritoneal tissue. 
-SMA-positive myofibroblasts are derived from resident fibroblasts, and fibroblast–
myofibroblast differentiation is mainly mediated by TGF- [30].  Therefore, we also 
evaluated the levels of TGF--expressing cells.  In the MGO group, the number of TGF--
expressing cells was higher than that of the control group (Fig. 4C and Table).  However, the 
EGCG group contained fewer TGF--expressing cells (Fig. 4D and Table). 
 
3.4. Expression of 8-OHdG 
EGCG is known to possess an anti-oxidative effect [17].  Therefore, we evaluated 8-OHdG 
as a marker of oxidative stress.  We found that 8-OHdG-expressing cells were mainly located 
in the submesothelial compact zone.  However, the numbers of 8-OHdG-expressing cells 
differed significantly between the groups.  In the control group, the number of 8-OHdG-
expressing cells was slightly higher than that of normal mice (data not shown).  In the MGO 
group, the number of 8-OHdG-expressing cells was higher than that of the control group (Fig. 
4E and Table).  Meanwhile, the EGCG group contained fewer 8-OHdG-expressing cells (Fig. 




3.5. Expression of CD31 and VEGF 
We investigated angiogenesis in peritoneal fibrosis, and quantified the number of CD31-
positive blood vessels.  In the MGO group, the number of blood vessels was markedly higher 
than in the control group (Fig. 5A and Table).  However, the EGCG group contained fewer 
blood vessels (Fig. 5B and Table). 
VEGF is a potent stimulator of angiogenesis.  Therefore, we evaluated VEGF in the 
peritoneal tissue.  In the MGO group, the number of VEGF-expressing cells was markedly 
higher than in the control group (Fig. 5C and Table).  However, the EGCG group contained 
fewer VEGF-expressing cells in the submesothelial zone (Fig. 5D and Table). 
 
3.6. Expression of F4/80 and MCP-1 
To investigate inflammation, we stained sections with anti-F4/80 antibody, as a marker of 
macrophages.  In the MGO group, we observed numerous macrophages in the thickened 
peritoneal tissues (Fig. 5E and Table).  However, the EGCG group contained significantly 
fewer macrophages than did the MGO group (Fig. 5F). 
We also investigated the levels of MCP-1-expressing cells, which exert an important effect 
on macrophage infiltration.  In the MGO group, the number of MCP-1-expressing cells was 
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significantly higher than that in the control group (Fig. 5G and Table).  Compared to the 
MGO group, the EGCG group contained significantly fewer MCP-1-expressing cells (Fig. 
5H and Table). 
 
3.7. Southwestern histochemistry for NF-B 
EGCG has been shown to suppress NF-B signaling [31, 32].  Therefore, we investigated 
the expression of activated NF-B in our model.  Southwestern histochemistry is used to 
detect activated transcription regulatory factors that bind to specific sequences of DNA [25, 
26]. 
The number of NF-B-activated cells in the submesothelial compact zone of the MGO 
group was significantly higher than that of the control group (Fig. 6A, B, and D).  Compared 
to the MGO group, the EGCG group contained significantly fewer NF-B-activated cells 
(Figure 6C and D).  To evaluate the specificity, we performed the same procedure using a 
mutated probe.  In this case, only a weak nuclear staining for NF-B was detected (data not 
shown).  When an excess amount of non-labeled probe was added to the standard mixture 





In the present study, MGO administration markedly increased the thickness of the 
submesothelial compact zone, the number of blood vessels and macrophages, and the 
intensity of immunohistochemical staining for CML in the mouse peritoneum.  Moreover, 
mice died from colon adhesion and we observed the formation of abdominal cocoons (data 
not shown).  All of these changes, reflecting the features of human peritoneal fibrosis, were 
significantly suppressed in the EGCG group.  Our results strongly indicate that EGCG 
ameliorates peritoneal fibrosis. 
The underlying mechanisms of encapsulating peritoneal sclerosis (EPS) in humans are not 
fully understood.  With respect to vasculopathy in the MGO-induced peritoneal fibrosis 
model, the number of vessels increased in the MGO group, which is similar to human 
peritoneal fibrosis [1].  However, it was difficult to evaluate morphological changes in the 
vessels because of the small size of the vessels in mice.  In the perineum of patients on long-
term peritoneal dialysis, vasculopathy tends to occur in post-capillary venules or capillaries 
and is marked by stenosis or obstruction of the vascular lumen caused by thickening and 
hyalinization of the vessels [1, 33]. 
Although structural changes could not be evaluated in detail, we found no intraluminal 
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stenosis or obstruction in our peritoneal fibrosis model.  Vasculopathy in this peritoneal 
fibrosis model may be somewhat different from that of human peritoneal fibrosis.  One 
possible explanation for this may be the different time course and contributing factors to the 
development of fibrosis in humans and the mouse model. 
Not limited to vasculopathy, it is difficult to establish an equivalent animal model for EPS.  
However, peritoneal fibrosis is essential to the development of EPS [4], and therefore, the 
prevention of peritoneal fibrosis is important to avoid EPS.  Although chlorhexidine 
gluconate -induced peritoneal fibrosis is a well-established animal model, its principal 
mechanism is chemical irritation of mesothelial cells.  By contrast, GDPs are thought to 
induce peritoneal fibrosis in humans, and therefore, MGO-induced peritoneal fibrosis more 
closely resembles human peritoneal fibrosis [34].  Several researchers have used a rat MGO-
induced peritoneal fibrosis model [7, 14, 34].  However, to our knowledge, this is the first 
study to use a mouse MGO-induced peritoneal fibrosis model.  The rat MGO models are 
limited by lack of specificity, and transient efficacy of pharmacologic agents and expression 
protocols.  Genetically modified mice could provide an attractive alternative to such models.  
The concentrations of MGO used in the rat MGO-induced peritoneal fibrosis model [7, 14, 
34] were <20 mM.  However, in mice, we were unable to induce sufficient peritoneal 
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thickness using 20 mM MGO.  This may reflect a species-dependent difference.  Thus, we 
adopted the experimental protocol described in the Materials and methods. 
Accumulated evidence indicates that GDPs can react with protein and generate AGEs, 
which are known to be important precursors of peritoneal fibrosis.  The extent of AGEs and 
RAGE expression in the peritoneal submesothelial compact zone has been shown to correlate 
with the duration of PD therapy [8, 13].  In general, RAGE is expressed in a variety of cell 
types, including endothelial cells, vascular smooth muscle cells, macrophages, mesangial 
cells, and neurons [35].  RAGE expression is low during homeostasis, but strikingly 
enhanced in conditions such as diabetes, uremia, and inflammation [10].  The AGEs–RAGE 
interaction activates numerous signaling cascades, including the MAPK cascade and NF-B 
signaling, and plays an important role in peritoneal fibrosis.  The interaction also mediates the 
generation of reactive oxygen species (ROS), which in turn activate TGF--Smad signaling 
[12, 16].  In the present study, we observed an increase in TGF--positive cells, and also in 8-
OHdG-positive cells, following the administration of MGO.  Our results suggest that the 
generation of ROS may increase the activity of TGF-. 
We have demonstrated for the first time that EGCG attenuates MGO-induced peritoneal 
fibrosis.  Previous reports have revealed that EGCG inhibits the nuclear translocation of NF-
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B [36], the phosphorylating activity of inhibitory B kinase-β [37], and the phosphorylation 
of the MAPK cascade [38], which is upstream of NF-B.  Suppression of NF-B activation 
has been linked with anti-inflammatory and anti-angiogenesis activity.  Thus, we postulated 
that EGCG exerts its inhibitory effects on MCP-1 and VEGF expression, at least in part, 
through the suppression of NF-B activity.  We analyzed activated NF-B expression using 
Southwestern histochemistry and observed that the levels of NF-B activation correlated with 
the progression of peritoneal thickness, and also with the expression levels of MCP-1 and 
VEGF. 
EGCG should be administrated intraperitoneally, intravenously, or subcutaneously, while 
considering the involvement of liver metabolism and glucuronidation of EGCG following 
oral administration [39, 40].  For intraperitoneal injection, direct interaction between EGCG 
and MGO should be considered.  In addition, repeated intravenous injections were technically 
difficult and created the potential for procedural artifacts in our study.  According to the 
literature, the bioavailability of subcutaneously injected EGCG was superior to that of the 
orally administered drug [41].  Thus, we adopted the subcutaneous injection of EGCG as the 
route of administration. 
We considered the possibility that EGCG pharmacologically inhibits MGO since Wu et al. 
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showed that EGCG prevented production of AGEs in vitro [42].  Therefore, we adopted 
different EGCG and MGO administration methods to minimize the impact of EGCG on 
MGO-derived AGE production in our study.  To clarify the precise mechanisms of EGCG 
prevention of MGO-induced peritoneal fibrosis, further investigations will be needed. 
The amount of EGCG used in our study was almost 10 times higher than that contained in 
daily drinking tea [43].  A previous report demonstrated that daily administration of 200 
mg/kg EGCG did not induce toxicity in rats during short-term observation [44].  In our 
pathophysiological investigation, there was no difference in the liver and kidney tissues of the 
PD fluid + EGCG and control groups.  Moreover, there was no difference in serum creatinine 
levels at 3 weeks (data not shown).  However, according to the reference, long-term and high-
dose EGCG administration can induce liver toxicity [45].  The appropriate quantity and 
method of administration for humans, and the long-term toxicity should be examined prior to 
clinical application. 
In conclusion, we have shown for the first time that EGCG inhibits the progression of 
peritoneal fibrosis in a mouse MGO-induced peritoneal fibrosis model.  Our results indicate 
that EGCG inhibits AGEs-induced upregulation of MCP-1 and VEGF, via inhibition of NF-
B activation and ROS generation.  Thus, EGCG represents a potentially novel candidate for 
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the treatment of peritoneal fibrosis. 
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Fig. 1.  Masson-trichrome staining of peritoneal tissues.  (A) In normal mice, note the 
monolayer of mesothelial cells covered with the surface of peritoneum.  (B) In the control 
group, injected with PD fluid and saline, the peritoneum is only slightly thickened.  (C) MGO 
injection induced significant thickening of the peritoneum.  (D) Administration of EGCG in 
MGO-treated mice significantly suppressed the progression of peritoneal thickening.  (E) 
Repeated injections of EGCG had little effect on peritoneal thickening compared with the 
control group.  (A–E), magnification ×200; bars indicate the thickness of the submesothelial 
compact zone.  (F) Bar graph showing the thickness of the submesothelial compact zone.  




Fig. 2.  The positive area of CML and the number of RAGE-expressing cells in 
peritoneal tissues.  (A) Note the low level of CML deposition in the peritoneal tissues of the 
control group.  (B) MGO injection induced a significant increase in CML deposition in the 
thickened peritoneum.  (C) In comparison with the MGO group, the EGCG group showed 
reduced intensity of CML staining in the peritoneum.  (A–C) magnification, ×200; bars 
indicate the thickness of the submesothelial compact zone.  (D) Bar graph showing positive 
area of CML in the peritoneal tissues.  Data are expressed as mean ± SEM; * p < 0.01.  (E) 
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Note the low level of RAGE expression in the control group.  (F) MGO injection strongly 
increased RAGE expression in the submesothelial compact zone and the vascular wall.  (G) In 
the EGCG group, the intensity of staining was significantly reduced.  (E–G) magnification, 
×200; bars indicate the thickness of the submesothelial compact zone.  (H) Bar graph showing 





Fig. 3.  The positive area of type III collagen in submesothelial compact zone.  (A) In the 
control group, type III collagen expression in the submesothelial compact zone was 
equivalent to that of normal mice.  (B) In the MGO group, the positive area of type III 
collagen in the submesothelial compact zone was significantly increased compared with the 
control group.  (C) In comparison with the MGO group, the deposition of type III collagen in 
the EGCG group was significantly reduced (C).  (A–C) magnification, ×200; bars indicate the 
thickness of the submesothelial compact zone.  (D) Bar graph showing the positive area of 
type III collagen in the submesothelial compact zone.  Data are expressed as mean ± SEM; * 





Fig. 4.  Immunohistochemistry for -SMA, TGF-, and 8-OHdG.  (A) Note the presence 
of numerous -SMA-expressing cells in the thickened submesothelial compact zone of the 
MGO group.  (B) In the EGCG group, the number of -SMA-expressing cells was reduced.  
(C) Note the strong expression of TGF- in the thickened submesothelial compact zone of the 
MGO group.  (D) In the EGCG group, the expression of TGF- was decreased.  (E) Note the 
strong expression of 8-OHdG in the thickened submesothelial compact zone of the MGO 
group.  (F) In the EGCG group, the expression of 8-OHdG was decreased.  (A–F) 





Fig. 5.  Immunohistochemistry for CD31, VEGF, F4/80, and MCP-1.  (A) Note the 
presence of numerous vessels positively stained for CD31 in the MGO group.  (B) In the 
EGCG group, only a few vessels stained positively for CD31.  (C) Note the large number of 
VEGF-expressing cells in the MGO group.  (D) In the EGCG group, the number of VEGF-
expressing cells was decreased.  (E) F4/80-positive macrophages were present in thickened 
peritoneal tissues of the MGO group.  (F) In the EGCG group, the number of F4/80-positive 
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macrophages was reduced.  (G) Note the strong expression of MCP-1-positive cells in the 
markedly thickened submesothelial compact zone of the MGO group.  (H) In the EGCG 
group, the number of MCP-1-positive cells in the submesothelial compact zone was decreased.  





Fig. 6.  Southwestern histochemistry for activated NF-B.  (A) In the control group, few 
NF-B-activated cells were present in the mesothelial layer.  (B) MGO injection induced a 
significant increase in the number of NF-B-activated cells in the submesothelial compact 
zone.  (C) In comparison with the MGO group, the EGCG group contained significantly 
fewer NF-B-activated cells in the submesothelial compact zone.  (A–C) magnification, 
×200; bars indicate the thickness of the submesothelial compact zone.  (D) Bar graph showing 
the number of NF-B-activated cells in the submesothelial compact zone.  Data are expressed 
as mean ± SEM; * p < 0.01. 
Number of positive cells in the peritoneum
Control group MGO group EGCG group
These data were determined in 5 fields of the submesothelial area 
selected at random in each mouse and examined at x 200 magnification.
Values are given as mean ±SEM
a p < 0.01 vs. Control group.






























Table: Results of immunohistochemistry for TGF-β, α-SMA,
8-OHdG, CD31, VEGF, F4/80, and MCP-1
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